Vascular targeting of anti-CD40 antibodies and IL-2 into autochthonous tumors enhances immunotherapy in mice
J. Clin. Invest. Juliana Hamzah, et al. 118:1691 doi:10.1172/JCI33201 [Go to this article.]

Figure 1
Delivery of RGR-fusion compounds into RIP1-Tag5 tumors. (A) Anti-CD40 antibodies and RGR-conjugated antibodies were separated on a nonreducing SDS/PAGE. Antibodies were visualized with an anti-rat IgG antibody. Successful conjugation with myc-tagged RGR peptide was demonstrated by reprobing the membrane with anti-myc antibodies. (B) Proliferation of IL-2–dependent CTL.L2 T cells after incubation with serial dilutions of commercial recombinant human (h) IL-2, bacterially expressed murine (m) IL-2, IL-2–RGR fusion product, and GST-tag alone as control. (C) Accumulation of 100 μg anti-CD40–RGR antibodies and (D) 100 μg IL-2–RGR in RIP1-Tag5 tumors 5 minutes after i.v. injection. Arrows highlight immune reactivity on blood vessels. (E) Serum alanine aminotransferase (ALT) values and (F) serum TNF-α of different treatment groups analyzed after 2 weeks of treatment (Figure 2A). Controls are untreated 25-week-old RIP1-Tag5 mice and mice injected with rat IgG plus RGR peptide. Original magnification, ×20 (C); ×40 (D). Scale bar: 50 μm (C); 25 μm (D).